Objective
to report the 36-month safety and efficacy of catheter-based renal denervation (RDN) in patients with uncontrolled hypertension
Study
single-blind, multicentre, sham-controlled randomised trial
Population
patients with office systolic BP at least 150mg Hg but less than 180mm Hg, office diastolic BP at least 140mg Hg but less than 170mm Hg and were taking one to three antihypertension medications
Endpoints
the difference of blood pressure measurements between RDN and sham control up to 36 months
Conclusion
renal denervation was associated with a lasting blood pressure reduction up to 36 months as compared to sham control
Mahfoud et al. Lancet. 2022;399:1401-10
